These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9568060)

  • 1. Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats.
    Breeman WA; de Jong M; Bernard B; Hofland LJ; Srinivasan A; van der Pluijm M; Bakker WH; Visser TJ; Krenning EP
    Anticancer Res; 1998; 18(1A):83-9. PubMed ID: 9568060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
    Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery.
    Hofland LJ; Breeman WA; Krenning EP; de Jong M; Waaijers M; van Koetsveld PM; Mäcke HR; Lamberts SW
    Proc Assoc Am Physicians; 1999; 111(1):63-9. PubMed ID: 9893158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
    Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary handling of iodine-125-Tyr3-octreotide and indium-111-DTPA-D-Phe1-octreotide by isolated perfused rat liver.
    de Jong M; Bakker WH; Breeman WA; van der Pluijm ME; Kooij PP; Visser TJ; Docter R; Krenning EP
    J Nucl Med; 1993 Nov; 34(11):2025-30. PubMed ID: 8229254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
    Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
    J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bernard BF; De Bruin E; Van Gameren A; Bakker WH; Visser TJ; Mäcke HR; Krenning EP
    Nucl Med Commun; 1998 Mar; 19(3):283-8. PubMed ID: 9625504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
    Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
    Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
    de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
    Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
    J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on radiolabeled somatostatin analogues in rats and in patients.
    Breeman WA; Bakker WH; De Jong M; Hofland LJ; Kwekkeboom DJ; Kooij PP; Visser TJ; Krenning EP
    Q J Nucl Med; 1996 Sep; 40(3):209-20. PubMed ID: 8961800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
    Siehler S; Seuwen K; Hoyer D
    Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
    Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodination of [Tyr11]somatostatin yields a super high affinity ligand for somatostatin receptors in GH4C1 pituitary cells.
    Presky DH; Schonbrunn A
    Mol Pharmacol; 1988 Nov; 34(5):651-8. PubMed ID: 2904115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM; Stolz B; Albert R; Ruser G; Briner U; Mäcke HR; Bruns C
    Nucl Med Biol; 1998 Apr; 25(3):181-8. PubMed ID: 9620621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.